tibulizumab   Click here for help

GtoPdb Ligand ID: 10350

Synonyms: LY-3090106 | LY3090106
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tibulizumab (LY3090106) is an investigational bispecific monoclonal antibody. It is a humanized antibody that simultaneously targets IL-17A and BAFF (TNFSF13B; CD257), that was produced by Eli Lilly as a potential therapeutic for IL-17-driven autoimmune diseases. Peptide sequences for tibulizumab (accessed from IMGT) are 100% matches with SEQ IDs 1 and 2 from patent WO2013158577A1, entitled 'Anti-baff-anti-il-17 bispecific antibodies' [1]. Tibulizumab neutralises IL-17 and BAFF bioactivities in vitro and in vivo [1].
Bioactivity Comments
Tibulizumab binds the IL-17A/IL-17F heterodimer with a Kd of ~90 pM [1]. It binds both soluble and membrane-bound BAFF.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-17A Primary target of this compound Hs Antibody Binding 10.9 pKd - 1
⤷ pKd 10.9 (Kd 1.4x10-11 M) [1]
BAFF Primary target of this compound Hs Antibody Binding 10.2 pKd - 1
⤷ pKd 10.2 (Kd 6x10-11 M) [1]